Atossa Therapeutics (ATOS) Long-Term Investments (2022 - 2024)

Atossa Therapeutics (ATOS) has reported Long-Term Investments for 3 consecutive years, with $1.7 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Long-Term Investments changed 0.0% year-over-year to $1.7 million; the TTM figure through Jun 2024 stood at $1.7 million (changed 0.0% YoY), while the FY2023 annual figure was $1.7 million, down 63.62% from the prior year.
• Long-Term Investments held at $1.7 million in Q2 2024 per ATOS's latest filing, from $1.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $4.7 million in Q4 2022 and bottomed at $1.7 million in Q2 2023.
• Historically, Long-Term Investments has averaged $2.6 million across 3 years, with a median of $1.7 million in 2023.
• Annual changes were most pronounced in 2023 — Long-Term Investments sank 63.62% — and 2024, when it changed 0.0%.
• Atossa Therapeutics' Long-Term Investments stood at $4.7 million in 2022, then tumbled by 63.62% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024.
• Business Quant data shows ATOS's Long-Term Investments at $1.7 million in Q2 2024, $1.7 million in Q1 2024, and $1.7 million in Q4 2023.